Antitumor and other effects of 24R,25-dihydroxycholecalciferol in Lewis lung carcinoma causing abnormal calcium metabolism in tumor-bearing mice

Y Maeda; H Yamato; T Hirai; N Kobori; T Fujii; Y Kobayashi; K Saitoh; E Inoguchi; M Hakozaki; H Iijima

doi:10.1159/000226562

Antitumor and other effects of 24R,25-dihydroxycholecalciferol in Lewis lung carcinoma causing abnormal calcium metabolism in tumor-bearing mice

Oncology. 1988;45(3):202-5. doi: 10.1159/000226562.

Authors

Y Maeda¹, H Yamato, T Hirai, N Kobori, T Fujii, Y Kobayashi, K Saitoh, E Inoguchi, M Hakozaki, H Iijima, et al.

Affiliation

¹ Biomedical Research Laboratories, Kureha Chemical Industry Co., Ltd., Tokyo, Japan.

PMID: 3368196
DOI: 10.1159/000226562

Abstract

Lewis lung carcinoma was found to cause hypercalcemia in tumor-bearing mice. 24R,25(OH)2D3 (K-DR, prepared by Kureha Chemical Ind.) significantly prolonged the survival time of mice with Lewis lung carcinoma. K-DR exhibited an antimetastatic effect on Lewis lung carcinoma, and also had an analgesic effect in mice with Lewis lung carcinoma.

MeSH terms

Analgesics / therapeutic use
Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Calcium / metabolism*
Carcinoma / complications
Carcinoma / drug therapy*
Carcinoma / metabolism
Dihydroxycholecalciferols / pharmacology
Dihydroxycholecalciferols / therapeutic use*
Hypercalcemia / drug therapy
Hypercalcemia / etiology*
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Male
Mice
Mice, Inbred C57BL
Mice, Inbred ICR
Neoplasm Metastasis / prevention & control

Substances

Analgesics
Antineoplastic Agents
Dihydroxycholecalciferols
25,26-dihydroxycholecalciferol
Calcium